Publications

Filter Publications By:

ARRY-382 / CSF1R

11/10/2017

Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

A phase 1b/2 dose-escalation study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF-1R) in combination with pembrolizumab for the treatment of patients with advanced solid tumors

Wael A. Harb, et al.

Binimetinib / Cancer

09/10/2017

European Society for Medical Oncology Congress

Quality of Life in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib Monotherapy in BRAF-Mutant Melanoma

Helen J. Gogas, et al.

Binimetinib / Cancer

09/10/2017

European Society for Medical Oncology Congress

Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib Monotherapy in BRAF-Mutant Melanoma

Ana Arance, et al.

Binimetinib and Encorafenib

09/09/2017

European Society for Medical Oncology Congress

RESULTS OF COLUMBUS PART 2: A Phase 3 Trial of Encorafenib Plus Binimetinib Versus Encorafenib in BRAF-Mutant Melanoma

R. Dummer, et al.

Binimetinib / Cancer

09/09/2017

BEACON CRC: Safety Lead-In (SLI) for the Combination of Binimetinib (BINI), Encorafenib (ENCO), and Cetuximab (CTX) in Patients (Pts) with BRAFV600E Metastatic Colorectal Cancer (mCRC)

Huijberts, et al.

Binimetinib / Cancer

06/03/2017

American Society of Clinical Oncology Meeting

Phase 1b/2 Trial of Ribociclib + Binimetinib in Metastatic NRAS-Mutant Melanoma: Safety, Efficacy, and Recommended Phase 2 Dose

Martin Schuler, et al.

Binimetinib and Encorafenib

11/09/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Results of COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

Keith T. Flaherty, M.D., et al.

Binimetinib / Cancer

11/07/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Management of MEK inhibitor (MEKi) toxicities of binimetinib (BINI) in the NEMO trial

Paolo A. Ascierto, M.D., et al.

Binimetinib / Cancer

11/07/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Efficacy of binimetinib in patients with NRAS-mutant melanoma: subgroup analysis of the phase 3 NEMO study

Ana Arance, M.D., et al.

ARRY-797 / LMNA DCM

08/31/2016

European Society of Cardiology Congress 2016

Phase 2 Study of A797, an Oral, Selective p38 Mitogen-Activated Protein Kinase Inhibitor, in Patients With Lamin A/C–Related Dilated Cardiomyopathy

Calum A. MacRae, M.D., Ph.D. et al.